Monitoring frequency guidelines CKD stage GFR range (mL/min/1.73 m2) PTH (pg/mL) Alkaline phosphatase (U/L) Calcium and phosphorus (mg/dL) CKD1 T >90 Once in the first 3 months and then every…

Primary glomerular disease Systemic disease Metabolic disease De novo disease Focal segmental glomerulosclerosis Systemic lupus erythematosus Diabetic nephropathy Membranous nephropathy IgA nephropathy Henoch–Schonlein purpura Oxalosis Anti-GBM disease MPGN type I…

Serologies Cytomegalovirus Herpes simplex virus 1 and 2 Hepatitis A, B, and C viruses Epstein–Barr virus (EBV) Varicella zoster virus Human immunodeficiency virus Rapid plasma regain Tuberculin skin test or…

Type of liver insult Setting Characteristic findings Ischemic hepatic injury Hypotension during surgery but may also occur with severe volume depletion and hepatic hypoperfusion at any time posttransplant Marked but…

Fig. 21.1 Components of TAH Diagnostic Considerations While both the World Health Organization and ADA definitions are accepted, we prefer the ADA based on a slightly higher level of stringency…

Fig. 4.1 United Network for Organ Sharing national kidney wait list additions and composition by active status Facts and Figures Since UNOS began keeping records in 1987, over 500,000 organ…

Dyslipidemia Goal Initiate Increase Alternative TG > 500 mg/dL with LDL < 100 mg/dL TG < 500 mg/dL TLC TLC + niacin Fibrate or statin LDL 100–129 mg/dL LDL < 100 mg/dL TLC TLC + low-dose statin Ezetimibe or niacin LDL > 100 mg/dL…

Medication Mechanism Incidence References mTOR inhibitors Myelosuppression 10–45 % [31] Antithymocyte globulins Myelosuppression, DITP 10–44 % [6, 19] Valproate DITP, myelosuppression 5–30 % [55] Azathioprine Myelosuppression 10–15 % [51] Ganciclovir/valganciclovir…